Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

PharmiWeb

People with blue dots

Can you survive without the blue dot?

Or has the digital world has replaced our brain

Page & Page Health

- PMLiVE

Novartis eyes potential new indication for Cosentyx

Unveils positive late-stage results in axial spondyloarthritis

- PMLiVE

Acceleron scraps rare muscular dystrophy drug

Clinical profile not strong enough to push into late-stage testing

- PMLiVE

J&J’s Tremfya filed for approval in US for psoriatic arthritis

Seeking share of increasingly competitive psoriasis market

- PMLiVE

New data backs GeNeuro’s MS drug after Servier exit

Search continues for new development partner

- PMLiVE

A roadmap to the successful treatment of Alzheimer’s disease

Building on past research to learn more about the disease and how to treat it

- PMLiVE

Envision Pharma Group relocates to support expansion

Office moves in the US prompted by significant growth

- PMLiVE

Trust: the ultimate elevator

By Andreas Reinbolz, Daniel Schäfer and Ralf Steinmetz

- PMLiVE

Biogen and Eisai drop Alzheimer’s drug elenbecestat

Latest blow in string of failures for BACE inhibitor category

- PMLiVE

Aimmune gets FDA panel backing for peanut allergy therapy

Step closer to becoming first approved treatment

AstraZeneca AZ

FDA fast-tracks AstraZeneca’s Farxiga in heart failure

Races to become first-in-class

- PMLiVE

Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder

Continues to bulk up its pipeline

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links